Latest Us Commercialisation News

HeraMED has moved its Lee Health digital maternity program from a six-month pilot into a paid deployment covering an initial 200 mothers. The milestone brings commercial revenue, but the company still faces a short cash runway as it works to scale the US rollout.

Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.

Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.

Knosys has moved its Libero library platform into active US commercialisation, identifying near-term sales opportunities while preparing for its first customer engagements. The push comes as ARR slips to A$8.7 million and a timing-affected quarter leaves the company with 2.03 quarters of estimated funding.

Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.

BlinkLab has reported 82% sensitivity and 83% specificity from an exploratory ADHD study in 208 children, while preparing a US regulatory program for a second product. Its autism diagnostic remains on track for pivotal study completion this quarter, with A$16.2 million in cash at 30 September.

LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.

Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.

Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.

Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.

Iondrive has formally entered Oklahoma’s Quality Jobs qualification process, advancing potential US$5.2 million in State and local benefits for its first US rare earth recycling module. The broader incentive framework could exceed US$15 million across three modules, but no funding has yet been awarded.

Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.